中医药治疗去势抵抗性前列腺癌的研究进展
|
摘要
前列腺癌发病率不断升高,且不可避免地会进展成为去势抵抗性前列腺癌,虽然治疗方式在不断更新,但预后仍不乐观。因中医药在增效减毒、提高生活质量、延长生存时间等方面的独特优势,其在去势抵抗性前列腺癌治疗中占据了非常重要的位置。对目前中医药治疗去势抵抗性前列腺癌的临床及基础研究进行归纳总结,为其临床治疗用药及基础研究提供借鉴。
The incidence of prostate cancer is increasing, and inevitably progresses to castration-resistant prostate cancer. Although the treatment is constantly updated, the prognosis is still not optimistic. Because of its unique advantages of effect-enhancing and toxicity-reducing, improving quality of life, and prolonging survival time, Chinese medicine has occupied a very important position in the treatment of castration resistant prostate cancer. This article summarizes the clinical and basic research of traditional Chinese medicine in the treatment of castration-resistant prostate cancer, and provides reference for clinical treatment and basic research.
The incidence of prostate cancer is increasing, and inevitably progresses to castration-resistant prostate cancer. Although the treatment is constantly updated, the prognosis is still not optimistic. Because of its unique advantages of effect-enhancing and toxicity-reducing, improving quality of life, and prolonging survival time, Chinese medicine has occupied a very important position in the treatment of castration resistant prostate cancer. This article summarizes the clinical and basic research of traditional Chinese medicine in the treatment of castration-resistant prostate cancer, and provides reference for clinical treatment and basic research.
引文
[1]Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]Siegel R L,Miller K D,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[3]韩苏军,张思维,陈万青,等.中国前列腺肿瘤发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[4]汪康宁,廖秋玲,陈烈钳,等.前列腺癌患者生存质量及影响因素分析[J].中国男科学杂志,2015,29(6):15-20.
[5]Chen W,Zheng R,Baade P D.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[6]Chen W,Sun K,Zheng R,et al.Cancer incidence and mortality in China,2014[J].Chin J Cancer Res,2018,30(1):1-12.
[7]孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2015.
[8]那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2013.
[9]中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.
[10]Courtney K D,Taplin M E.The evolving paradigm of second-line hormonal therapy options for castrationresistant prostate cancer[J].Curr Opin Oncol,2012,24(3):272-277.
[11]Kao S C,Hovey E,Marx G.Second-line therapy for castrate-resistant prostate cancer:A literature review[J].Asia Pac J Clin Oncol,2011,7(3):212-223.
[12]Heidenreich A,Bastian P J,Bellmunt J,et al.EAUguidelines on prostate cancer[J].Eur Urol,2014,65(2):467-479.
[13]贾玉森,陈小均,张志杰.中医药治疗前列腺癌的临床研究概况[J].中医杂志,2012,53(24):2142-2146.
[14]余炅,唐晓玲,熊林楷,等.熊墨年论肿瘤的中医辨证与治疗[J].中医杂志,2012,53(8):642-644.
[15]王金秀,李小江,陈军,等.贾英杰论前列腺癌的中医病机与治疗[J].新中医,2014,46(4):20-23.
[16]牟睿宇,李小江.贾英杰运用“截断疗法”治疗前列腺癌[J].辽宁中医杂志,2017,44(11):2296-2298.
[17]李想.贾英杰教授使用中药联合内分泌治疗前列腺癌报道1例[J].光明中医,2014,29(5):1062-1063.
[18]张扬,雷博涵,邹青,等.中西医结合治疗去势抵抗性前列腺癌的疗效观察[J].中华男科学,2017,23(10):922-927.
[19]卢子杰,雷博涵,张扬,等.补益肺肾、化瘀解毒法治疗去势抵抗性前列腺癌临床研究[J].新中医,2018,50(1):91-94.
[20]庞然,卢建新,高筱松,等.前列消癥汤治疗激素难治性前列腺癌的临床研究[J].中国中西医结合外科杂志,2013,19(4):374-377.
[21]陈永良,叶利洪,徐建兴,等.补肾益气汤联合化疗在激素扺抗性前列腺癌治疗中的应用研究[J].中华中医药学刊,2014,32(9):2276-2278.
[22]舒楠,陈子珺.激素非依赖性前列腺癌的中医药治疗研究进展[J].中华中医药学刊,2016,34(4):804-407.
[23]陈晓农,王荣江.参附注射液对晚期前列腺癌患者的PSA水平及生存质量的影响[J].中华中医药学刊,2014,32(6):1459-1461.
[24]张晓伟.复方苦参注射液联合多西他赛治疗激素难治性前列腺癌的临床观察[J].中国医药导刊,2013,15(3):501-504.
[25]吴炎卿,李旻霞.参芪扶正注射液对人前列腺癌PC-3细胞增殖的影响及机制研究[J].中医药导报,2017,23(6):51-56.
[26]吕立国,张娴,陈志强,等.参附注射液对前列腺癌PC-3细胞凋亡诱导的影响[J].中华男科学杂志,2014,20(6):539-543.
[27]郭明伟,侯凌波,谢建兴.穿心莲内酯对前列腺癌PC-3细胞的凋亡作用及机制研究[J].中药药理与临床,2015,31(6):18-20.
[28]周仕轶,王林,邵继春,等.度他雄胺和“扶正抑瘤”中药复方对人前列腺癌PC-3细胞转移抑制效应的对照研究[J].成都中医药大学学报,2015,38(2):10-15.
[29]唐冬,吕磊,曾甫清,等.藤黄酸抑制前列腺癌PC-3细胞增殖并诱导其细胞凋亡[J].肿瘤,2011,33(8):688-692.
[30]蔡剑,彭成,朱晓燕,等.广藿香醇对人雄激素非依赖性前列腺癌细胞DU145生长的抑制作用及机制[J].中国实验方剂学杂志,2014(10):165-169.
[31]邵继春,周仕轶,张蜀武.扶正抑瘤中药复方对人前列腺癌DU-145细胞凋亡影响及机制研究[J].中国男科学杂志,2016,30(4):13-18.
[32]邹佩良,张秋红,周建甫,等.重楼皂苷I通过ERK/P65/DNMT1通路抑制前列腺癌PC3细胞生长的分子机制[J].中华男科,2018,24(3):199-205.
[33]Liu K C,Yen C Y,Wu R,et al.The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells[J].Environ Toxicol,2014,29(4):428-439.
[34]Li X,Li X,Wang J,et al.Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells[J].Int J Biol Sci,2012,8(6):901-912.
[35]崔涛,高晶,曾勇,等.薏苡仁油对人前列腺癌PC-3细胞的抑制作用[J].中草药,2018,49(21):4460-4464.
[2]Siegel R L,Miller K D,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[3]韩苏军,张思维,陈万青,等.中国前列腺肿瘤发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[4]汪康宁,廖秋玲,陈烈钳,等.前列腺癌患者生存质量及影响因素分析[J].中国男科学杂志,2015,29(6):15-20.
[5]Chen W,Zheng R,Baade P D.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[6]Chen W,Sun K,Zheng R,et al.Cancer incidence and mortality in China,2014[J].Chin J Cancer Res,2018,30(1):1-12.
[7]孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2015.
[8]那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2013.
[9]中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.
[10]Courtney K D,Taplin M E.The evolving paradigm of second-line hormonal therapy options for castrationresistant prostate cancer[J].Curr Opin Oncol,2012,24(3):272-277.
[11]Kao S C,Hovey E,Marx G.Second-line therapy for castrate-resistant prostate cancer:A literature review[J].Asia Pac J Clin Oncol,2011,7(3):212-223.
[12]Heidenreich A,Bastian P J,Bellmunt J,et al.EAUguidelines on prostate cancer[J].Eur Urol,2014,65(2):467-479.
[13]贾玉森,陈小均,张志杰.中医药治疗前列腺癌的临床研究概况[J].中医杂志,2012,53(24):2142-2146.
[14]余炅,唐晓玲,熊林楷,等.熊墨年论肿瘤的中医辨证与治疗[J].中医杂志,2012,53(8):642-644.
[15]王金秀,李小江,陈军,等.贾英杰论前列腺癌的中医病机与治疗[J].新中医,2014,46(4):20-23.
[16]牟睿宇,李小江.贾英杰运用“截断疗法”治疗前列腺癌[J].辽宁中医杂志,2017,44(11):2296-2298.
[17]李想.贾英杰教授使用中药联合内分泌治疗前列腺癌报道1例[J].光明中医,2014,29(5):1062-1063.
[18]张扬,雷博涵,邹青,等.中西医结合治疗去势抵抗性前列腺癌的疗效观察[J].中华男科学,2017,23(10):922-927.
[19]卢子杰,雷博涵,张扬,等.补益肺肾、化瘀解毒法治疗去势抵抗性前列腺癌临床研究[J].新中医,2018,50(1):91-94.
[20]庞然,卢建新,高筱松,等.前列消癥汤治疗激素难治性前列腺癌的临床研究[J].中国中西医结合外科杂志,2013,19(4):374-377.
[21]陈永良,叶利洪,徐建兴,等.补肾益气汤联合化疗在激素扺抗性前列腺癌治疗中的应用研究[J].中华中医药学刊,2014,32(9):2276-2278.
[22]舒楠,陈子珺.激素非依赖性前列腺癌的中医药治疗研究进展[J].中华中医药学刊,2016,34(4):804-407.
[23]陈晓农,王荣江.参附注射液对晚期前列腺癌患者的PSA水平及生存质量的影响[J].中华中医药学刊,2014,32(6):1459-1461.
[24]张晓伟.复方苦参注射液联合多西他赛治疗激素难治性前列腺癌的临床观察[J].中国医药导刊,2013,15(3):501-504.
[25]吴炎卿,李旻霞.参芪扶正注射液对人前列腺癌PC-3细胞增殖的影响及机制研究[J].中医药导报,2017,23(6):51-56.
[26]吕立国,张娴,陈志强,等.参附注射液对前列腺癌PC-3细胞凋亡诱导的影响[J].中华男科学杂志,2014,20(6):539-543.
[27]郭明伟,侯凌波,谢建兴.穿心莲内酯对前列腺癌PC-3细胞的凋亡作用及机制研究[J].中药药理与临床,2015,31(6):18-20.
[28]周仕轶,王林,邵继春,等.度他雄胺和“扶正抑瘤”中药复方对人前列腺癌PC-3细胞转移抑制效应的对照研究[J].成都中医药大学学报,2015,38(2):10-15.
[29]唐冬,吕磊,曾甫清,等.藤黄酸抑制前列腺癌PC-3细胞增殖并诱导其细胞凋亡[J].肿瘤,2011,33(8):688-692.
[30]蔡剑,彭成,朱晓燕,等.广藿香醇对人雄激素非依赖性前列腺癌细胞DU145生长的抑制作用及机制[J].中国实验方剂学杂志,2014(10):165-169.
[31]邵继春,周仕轶,张蜀武.扶正抑瘤中药复方对人前列腺癌DU-145细胞凋亡影响及机制研究[J].中国男科学杂志,2016,30(4):13-18.
[32]邹佩良,张秋红,周建甫,等.重楼皂苷I通过ERK/P65/DNMT1通路抑制前列腺癌PC3细胞生长的分子机制[J].中华男科,2018,24(3):199-205.
[33]Liu K C,Yen C Y,Wu R,et al.The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells[J].Environ Toxicol,2014,29(4):428-439.
[34]Li X,Li X,Wang J,et al.Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells[J].Int J Biol Sci,2012,8(6):901-912.
[35]崔涛,高晶,曾勇,等.薏苡仁油对人前列腺癌PC-3细胞的抑制作用[J].中草药,2018,49(21):4460-4464.